All Stories

  1. Impact of Conditioning Regimen Intensity and Total Body Irradiation on Outcomes of Allogeneic Hematopoietic Cell Transplantation for Mature T-Cell Lymphomas: A Multicenter Analysis

    Article • Transplantation and Cellular Therapy, August 2026, Elsevier

    Dr. Talal Hilal

  2. Follicular Lymphoma: Novel Therapies and Strategies for Optimal Therapeutic Sequencing

    Article • Current Oncology Reports, July 2026, Springer Science + Business Media

    Dr. Talal Hilal

  3. Real-world outcomes of cilta-cel versus BCMA-targeting bispecific antibodies in relapsed/refractory multiple myeloma

    Article • Leukemia & Lymphoma, May 2026, Taylor & Francis

    Dr. Talal Hilal

  4. At the Crossroads of Lineage: Secondary Malignancies After CAR-Based Immunotherapy

    Article • Cancers, February 2026, MDPI AG

    Dr. Talal Hilal

  5. Trends in the design of FDA registrational randomised clinical trials in haematology and oncology: a 20-year cohort study

    Article • BMJ Connections Oncology, December 2025, BMJ

    Dr. Talal Hilal

  6. Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial

    Article • Journal of Clinical Oncology, November 2025, American Society of Clinical Oncology (ASCO)

    Dr. Talal Hilal

  7. Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access

    Article • Cancers, October 2025, MDPI AG

    Dr. Talal Hilal

  8. Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access

    Article • September 2025, MDPI AG

    Dr. Talal Hilal

  9. Chimeric antigen receptor T‐cell therapy for high‐grade B‐cell lymphoma NOS

    Article • British Journal of Haematology, July 2025, Wiley

    Dr. Talal Hilal

  10. SGLT2 inhibitors and cardiovascular outcomes in patients with multiple myeloma and concomitant type 2 diabetes mellitus

    Article • Leukemia & Lymphoma, July 2025, Taylor & Francis

    Dr. Talal Hilal

  11. Estimation of Benefit to Bispecific Antibodies in US Patients with Lymphoma and Multiple Myeloma

    Article • Blood Advances, July 2025, American Society of Hematology

    Dr. Talal Hilal

  12. Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis

    Article • Blood Neoplasia, February 2025, Elsevier

    Dr. Talal Hilal

  13. CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma

    Article • Blood Advances, October 2024, American Society of Hematology

    Dr. Talal Hilal

  14. IgG replacement in multiple myeloma

    Article • Blood Cancer Journal, July 2024, Springer Science + Business Media

    Dr. Talal Hilal

  15. Relationships Among Health Insurance Literacy, Financial Toxicity, and Sociodemographic Factors in Patients With Cancer

    Article • JCO Oncology Practice, October 2023, American Society of Clinical Oncology (ASCO)

    Dr. Talal Hilal

  16. Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma

    Article • Nature Reviews Clinical Oncology, September 2023, Springer Science + Business Media

    Dr. Talal Hilal

  17. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice

    Article • Current Treatment Options in Oncology, May 2023, Springer Science + Business Media

    Dr. Talal Hilal

  18. Allogeneic Hematopoietic Stem Cell Transplant for Diffuse Large B-Cell Lymphoma: Evolving Role in the Era of CAR T-Cell Therapy

    Article • Current Oncology Reports, March 2023, Springer Science + Business Media

    Dr. Talal Hilal

  19. Quality of the control arms in randomized trials of chronic lymphocytic leukemia enrolling in the USA: A systematic review

    Article • European Journal of Cancer, February 2023, Elsevier

    Dr. Talal Hilal

  20. Isolated CNS relapse of blastic plasmacytoid dendritic cell neoplasm

    Article • Blood, February 2022, American Society of Hematology

    Dr. Talal Hilal

  21. Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity

    Article • Leukemia Supplements, June 2020, Springer Science + Business Media

    Dr. Talal Hilal

  22. Primary Central Nervous System Lymphoma: Consensus, Controversies and Future Directions

    Article • Advances in Cell and Gene Therapy, March 2020, Wiley

    Dr. Talal Hilal

  23. Change in 21‐gene Recurrence Score result after exposure to neo‐adjuvant endocrine therapy in patients with operable breast cancer

    Article • The Breast Journal, December 2019, Wiley

    Dr. Talal Hilal

  24. Gone But Here

    Article • American Journal of Hospice and Palliative Medicine®, October 2019, SAGE Publications

    Dr. Talal Hilal

  25. Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma

    Article • Leukemia & Lymphoma, June 2019, Taylor & Francis

    Dr. Talal Hilal

  26. Hemostatic complications associated with ventricular assist devices

    Article • Research and Practice in Thrombosis and Haemostasis, June 2019, Wiley

    Dr. Talal Hilal

  27. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration

    Article • JAMA Oncology, June 2019, American Medical Association (AMA)

    Dr. Talal Hilal

  28. Hanging Up the Gloves

    Article • The Oncologist, May 2019, Alphamed Press

    Dr. Talal Hilal

  29. Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis

    Article • BMJ Supportive & Palliative Care, April 2019, BMJ

    Dr. Talal Hilal

  30. Germ Cell Tumors with Malignant Somatic Transformation: A Mayo Clinic Experience

    Article • Oncology Research and Treatment, January 2019, Karger Publishers

    Dr. Talal Hilal

  31. Erratum

    Article • Oncology Research and Treatment, January 2019, Karger Publishers

    Dr. Talal Hilal

  32. Outcome disparities in colorectal cancer: a SEER-based comparative analysis of racial subgroups

    Article • International Journal of Colorectal Disease, November 2018, Springer Science + Business Media

    Dr anas M. saad, Dr. Talal Hilal

  33. ASO Author Reflections: Role of Contrast-Enhanced Spectral Mammography in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic Therapy

    Article • Annals of Surgical Oncology, October 2018, Springer Science + Business Media

    Dr. Talal Hilal

  34. I Don’t Know

    Article • American Journal of Hospice and Palliative Medicine®, September 2018, SAGE Publications

    Dr. Talal Hilal

  35. Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission

    Article • Nature Reviews Clinical Oncology, September 2018, Springer Science + Business Media

    Dr. Talal Hilal

  36. Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis

    Article • American Journal of Hematology, September 2018, Wiley

    Dr. Talal Hilal

  37. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections

    Article • Blood Reviews, September 2018, Elsevier

    Dr. Talal Hilal

  38. Activity Of Imatinib In Clonal Extramedullary Myeloid Neoplasms With Eosinophilia

    Article • August 2018, Science Trends

    Dr. Talal Hilal

  39. Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy

    Article • The Breast Journal, July 2018, Wiley

    Dr. Talal Hilal

  40. Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia—the Burden of Novelty

    Article • Current Hematologic Malignancy Reports, July 2018, Springer Science + Business Media

    Dr. Talal Hilal

  41. Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma

    Article • JAMA Oncology, June 2018, American Medical Association (AMA)

    Dr. Talal Hilal

  42. Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis

    Article • European Urology Oncology, June 2018, Elsevier

    Dr. Talal Hilal

  43. Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma

    Article • New England Journal of Medicine, April 2018, New England Journal of Medicine (NEJM/MMS)

    Dr. Talal Hilal

  44. Necrobiotic xanthogranuloma: a 30-year single-center experience

    Article • Annals of Hematology, March 2018, Springer Science + Business Media

    Dr. Talal Hilal

  45. Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy

    Article • Annals of Surgical Oncology, March 2018, Springer Science + Business Media

    Dr. Talal Hilal

  46. Nivolumab-associated bone marrow necrosis

    Article • Annals of Oncology, January 2018, Oxford University Press (OUP)

    Dr. Talal Hilal

  47. A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma

    Article • Leukemia & Lymphoma, January 2018, Taylor & Francis

    Dr. Talal Hilal

  48. Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1 / PDGFRA rearrangement

    Article • Cancer Genetics, January 2018, Elsevier

    Dr. Talal Hilal

  49. B-cell acute lymphoblastic leukemia with +der(1)t(1;19) (p13;p13.1) arising in the setting of CALR exon 9 mutated essential thrombocythemia

    Article • Cancer Genetics, December 2017, Elsevier

    Dr. Talal Hilal

  50. Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy

    Article • BMC Cancer, August 2017, Springer Science + Business Media

    Dr. Talal Hilal

  51. Cytomegalovirus reactivation is associated with a lower rate of early relapse in myeloid malignancies independent of in-vivo T cell depletion strategy

    Article • Leukemia Research, June 2017, Elsevier

    Dr. Talal Hilal

  52. Update on lung neuroendocrine tumors

    Article • Therapeutic Advances in Medical Oncology, November 2016, SAGE Publications

    Dr. Talal Hilal

  53. ERBB2 (HER2)Testing in Breast Cancer

    Article • JAMA, March 2016, American Medical Association (AMA)

    Dr. Talal Hilal

  54. Radiation-induced breast cancer: the question of early breast cancer screening in Hodgkin's lymphoma survivors

    Article • Oxford Medical Case Reports, February 2016, Oxford University Press (OUP)

    Dr. Talal Hilal

  55. Unexpected Cardiac Masses

    Article • JAMA Oncology, December 2015, American Medical Association (AMA)

    Dr. Talal Hilal

  56. Exploring the possibilities: airspace disease in the postallogeneic haematopoietic stem cell transplant period

    Article • BMJ Case Reports, October 2015, BMJ

    Dr. Talal Hilal

  57. The Perils of Country Life: Human Monocytic Ehrlichiosis

    Article • The American Journal of Medicine, August 2015, Elsevier

    Dr. Talal Hilal

  58. Maintaining sharp focus on a grainy film: miliary pattern in an elderly woman with acute respiratory failure

    Article • BMJ Case Reports, July 2015, BMJ

    Dr. Talal Hilal

  59. Sudden cardiac arrest in a healthy young athlete

    Article • BMJ Case Reports, June 2015, BMJ

    Dr. Talal Hilal

  60. Bilateral upper lobe opacification

    Article • The Medical Journal of Australia, June 2015, Australasian Medical Publishing Co. Pty Ltd. (AMPCo)

    Dr. Talal Hilal

  61. Diffuse unresolving pulmonary nodules in a patient with a history of cervical carcinoma

    Article • BMJ Case Reports, April 2015, BMJ

    Dr. Talal Hilal

  62. A tick-borne illness unmasking asymptomatic Brugada syndrome

    Article • Oxford Medical Case Reports, February 2015, Oxford University Press (OUP)

    Dr. Talal Hilal

  63. Fatal Cytomegalovirus Disease after Combination Therapy with Corticosteroids and Rituximab for Granulomatosis with Polyangiitis

    Article • Case Reports in Rheumatology, January 2015, Hindawi Publishing Corporation

    Dr. Talal Hilal

  64. Disseminated tuberculosis with tuberculous meningitis in an immunocompetent host

    Article • Oxford Medical Case Reports, October 2014, Oxford University Press (OUP)

    Dr. Talal Hilal

  65. Chronic rupture of the coronary sinus of Valsalva with pseudoaneurysm formation

    Article • Oxford Medical Case Reports, October 2014, Oxford University Press (OUP)

    Dr. Talal Hilal

  66. A cause to consider for chronic unresolving diarrhea

    Article • Gastroenterology Report, October 2014, Oxford University Press (OUP)

    Dr. Talal Hilal

  67. Fulminant Wilson’s Disease Managed with Plasmapheresis as a Bridge to Liver Transplant

    Article • Case Reports in Medicine, January 2014, Hindawi Publishing Corporation

    Dr. Talal Hilal

  68. Isolated neurocutaneous peripheral T cell lymphoma, NOS

    Article • International Journal of Case Reports and Images, January 2014, Edorium Journals Pvt. Ltd.

    Dr. Talal Hilal